
The Effects of Dalfampridine Extended Release on Motor Function Beyond Walking in Multiple Sclerosis

Albert Lo, MD, PhD

Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Hartford, CT Brown University, Providence, RI


> Mandell Center for Multiple Sclerosis



Acknowledgements

- Elizabeth Triche, PhD (Co- PI)*
- Jennifer Ruiz, DPT
- Claire Koenig, PhD
- Kayla Olson, MA
- Beth Anderson, PhD

* Brown University & Mandell Multiple Sclerosis Center




Purpose

- Examine "responsiveness" to dalfampridine-ER in a clinical setting for outcomes beyond walking speed
 - To address anecdotal patient comments
- Goal: To identify potential alternative outcomes despite categorization of responder status based on walking speed.

Design

- Observational, prospective study
- Patients newly prescribed dalfampridine-ER for routine MS clinical care
- 14 weeks



Outcomes, (motor)					
Assessment	Test	Abbreviatior			
Gait Speed	Timed 25 Ft Walk	T25FW			
Gait Endurance	6 Minute Walk Test	6MW			
Dynamic Gait	Six Spot Step Test	SSST			
Self Perceived Walking Ability	12-Item MS Walking Scale	MSWS-12			
Upper Extremity – Fine Motor	9 Hole Peg Test	9HPT			
Upper Extremity – Gross Motor	Box and Blocks Test	BBT			
Data in this presentation were analyzed as baseline vs. week 14 comparisons All time points were used to define responder status. Baseline \rightarrow Week \rightarrow Week 7 \rightarrow Week 14 14					


Demographics					
mean ± SD (range)	Present Study (n=39)	Goodman 2009 (n=228)	Goodman 2010 (n=120)		
Age, years	54.1 ± 9.9 (21-67)	51.5 ± 8.8 (26–70)	51.8 ± 9.6 (25–73)		
Gender: n (%) Female Subtype, n (%)	31 (79.5%)	162 (71%)	88 (73%)		
Primary Progressive/ Progressive Relapsing	9 (23%)	41 (18%)	15 (12.5%)		
Relapse Remitting/ Secondary Progressive	30 (77%)	187 (82%)	105 (87.5%)		
Disease Duration	12.9 ± 8.8 (0.0-34.0)	13.4 ± 8.29 (0.4–41.7)	14.4 ± 9.5 (0.5–45.6)		


Demographics (Con't)


mean ± SD	Present Study	Goodman 2009*	Goodman 2010**
	(n=39)	(n=228)	(n=119)
EDSS Score	5.1 ± 1.6	5.8 ± 1.0	5.8 ± 1.0
T25FW, ft/sec	2.9 ± 1.5	2.1 ± 0.7	2.1 ± 0.8


*Goodman AD et al., (2009) Sustained –release oral fampridine in multiple sclerosis: a randomised , double-blind, controlled trial. Lancet 373(9665): 732-738.


**Goodman AD et al., (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68(4): 494-502.























MS Walking Scale-12


In the past two weeks, how much has your MS:	Not at all	A little	Moderately	Quite a bit	Extremely
1. Limited your ability to walk?	1	2	3	4	5
2. Limited your ability to run?	1	2	3	4	5
3. Limited your ability to climb up and down stairs?	1	2	3	4	5
4. Made standing when doing things more difficult?	1	2	3	4	5
5. Limited your balance when standing or walking?	1	2	3	4	5
6. Limited how far you are able to walk?	1	2	3	4	5
7. Increased the effort needed for you to walk?	1	2	3	4	5
8. Made it necessary for you to use support when walking indoors (e.g., using a stick, a frame, etc)?	1	2	3	4	5
9. Made it necessary for you to use support when walking outdoors (e.g., using a stick, a frame, etc)?	1	2	3	4	5
10. Slowed down your walking?	1	2	3	4	5
11. Affected how smoothly you walk?	1	2	3	4	5
12. Made you concentrate on your walking?	1	2	3	4	5
© 2000 Neurological Outcome Measures Unit, Institute of Neurology, University College Hospital.					














Summary Table: Baseline to Week 14 Lower Extremity

	OG (n=39)	TWR ^a (n=20)	TWNR ^a (n=8)
	p	p	p
6 Minute Walk Test (m) ^b	.021	.001	.764
MS Walking Scale: Total Score ^b	< .001	.001	.004
Timed 25 Ft Walk (sec) °	< .001	< .001	.484
Six Spot Step Test: (sec)			
Dominant Side ^c	< .001	.003	.310
Non-Dominant Side c	< .001	.023	.028

Summary Table: Baseline to Week 14 Upper Extremity

	OG (n=39)	TWR ^a (n=20)	TWNR ^a (n=8)
	p	р	p
Box & Block Test: (# Blocks)			
Dominant Side ^b	.005	.026	.001
Non-Dominant Side b	.001	.009	.084*
9 Hole Peg Test: (sec)			
Dominant Side ^c	< .001	.003	.017
Non-Dominant Side ^c	< .001	.020	.025

 $^{\rm a}$ On drug 100% of the time $$^{\rm b}$ Parametric analyses $$^{\circ}$Non-parametric analyses <math display="inline">*$ Trend towards a significant difference p < .10

lmprovement	Summary
6MW • OG: 10.61%* • TWR: 15.70%* • TWNR: 0.63%	MSWS-12 • OG: 19.63%* • TWR: 19.97%* • TWNR: 30.69%*
 SSST: Dominant Side OG: 14.90%* TWR: 16.74%* TWNR: 11.19% 	T25FW • OG: 11.54%* • TWR: 16.37%*
 SSST: Non-Dominant Side OG: 14.73%* TWR: 14.36%* TWNR: 13.50%* 	• TWNR: 2.61%

* Significant difference between baseline and week 14 data, p < .05

% Improvement Summary

BBT: Dominant Side

OG:TWR:TWNR:	6.05%* 6.18%* 11.74%*	
BBT: Non- • OG:	Dominant Side 6.41%*	
• TWR:	6.01%*	
TWNR:	4.58%**	


9HPT: Dominant Side

- OG: 7.02%*
- TWR: 7.25%*
- TWNR: 7.70%*

9HPT: Non-Dominant Side

- OG: 7.60%*
- TWR: 5.46%*
- TWNR: 6.44%*

*Significant difference between baseline and week 14 data, p< .05 ** Trend towards a significant difference between baseline and week 14 data, p < .10



Thank You Questions?

Future Analysis Areas

Cognitive Function Mood Fatigue Vision Pain Physical Fitness Overall Disability and Function Biomarkers of Disease Progression MRI Lesion Location